Biogen (BIIB) Free Cash Flow (2009 - 2026)

Biogen has reported Free Cash Flow for 18 years, with the latest figure at $408.0 million in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 203.8% year-over-year to $408.0 million in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 36.28% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, down 24.65% from the prior year.
• Free Cash Flow was $408.0 million for Q2 2026 at Biogen, down from $594.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $1.2 billion in Q3 2025, with the low at -$261.4 million in Q4 2022.
• Average Free Cash Flow over 5 years is $455.0 million, with a median of $487.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow slumped 133.23% in 2022, then surged 1469.26% in 2024.
• Over 5 years, Free Cash Flow stood at -$261.4 million in 2022, then surged by 79.84% to -$52.7 million in 2023, then soared by 1469.26% to $721.6 million in 2024, then sank by 35.14% to $468.0 million in 2025, then decreased by 12.82% to $408.0 million in 2026.
• The last three Free Cash Flow figures came in at $408.0 million (Q2 2026), $594.3 million (Q1 2026), and $468.0 million (Q4 2025), per Business Quant data.